Düsseldorf/Germany: After three fascinating and very interesting days, MEDICA 2019 ended on 21 November. Once again, the world’s leading medical trade fair was a huge success. At STORZ MEDICAL’s exhibition stand in hall 10, the full range of the company’s therapy options was on display – including several innovations. Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system, a unique procedure for patients with Alzheimer's disease, was explained in detail by Dr Rafael Storz, who also answered the visitors’ questions. In addition, the new MAGNETOLITH® for Extracorporeal Magnetotransduction Therapy (EMTT®) and the redesigned MODULITH® SLC were also at the centre of attention. Both devices were unveiled and presented during the trade fair.
The live webinar »Transcranial Pulse Stimulation (TPS) in Patients with Alzheimer`s Disease« with Prof. Dr Roland Beisteiner will be hosted by SOTERIX Medical in cooperation with STORZ MEDICAL.
Transcranial Pulse Stimulation (TPS) is a revolutionary new technique that delivers ultrasound-based pulse stimulation using shock waves.
In early January 2022, a study on the development of global dementia prevalence published by the medical journal The Lancet Public Health1 received a lot of attention. The study predicts that the number of cases will triple to 152.8 million by 2050.The World Alzheimer Report 2019 already came to a similar assessment. The most important factors for this explosive development are the ageing of the global population and its further growth.
»New hope for Alzheimer's patients: Patient's memory improves«*: On 22 April 2022, the front-page lead story of Germany's highest-circulation daily newspaper BILD (reach 7.62 million predominantly older readers) was about Transcranial Pulse Stimulation (TPS) with the NEUROLITH®. The full TPS article...
It's getting exciting: In the RTL News report »Neue Alzheimer-Therapie: Sanfte Stosswellen bringen Gedächtnis zurück«. Prof. Dr Musa Citak introduces in his practice in Hamburg the NEUROLITH® system and the treatment method, Transcranial Pulse Stimulation – short TPS.
TPS as a modern therapy method for the treatment of Alzheimer's dementia stimulates different brain regions even in deeper areas.
In 2019 the NEUROLITH® shock wave system was successfully introduced to the market. The Transcranial Pulse Stimulation (TPS) device, which was developed by STORZ MEDICAL in Switzerland, is the only medical device marketed in Europe that is approved in the European Union for the treatment of the central nervous system of patients with Alzheimer's disease. The effect of TPS is now being investigated in another neurological condition: In September 2020, the world's first clinical study for the treatment of Parkinson's patients with shock wave therapy using real-time documentation started at MedUni Vienna (Department of Neurology) in Austria under the direction of Professor Roland Beisteiner.
Transcranial Pulse Stimulation (TPS) continues to be on the road to success: The 100th NEUROLITH® system was installed at the beginning of June 2022. The latest TPS location is the Lengg Clinic in Zurich, Switzerland. Dr. med. Bartosz Bujan (Medical Director...
Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey.
Transcranial Pulse Stimulation (TPS) celebrates its debut in Ukraine: The first NEUROLITH® system was installed in the western Ukrainian city and cultural centre of Lviv (approx. 750,000 inhabitants) on 12 January 2022. Now, Alzheimer's patients can receive treatment at »BRAINSPOT LVIV«, a clinic for neuromodulation (Director: Tomas Dzeminskyy, Chief Medical Officer: Andrii Hul). The first therapy sessions have already taken place.
Alzheimer's patients now also have access to Transcranial Pulse Stimulation (TPS) in Munich – one of the leading medical cities in Germany. In July 2021, a NEUROLITH® system was installed in the private practice Schleicher & Brückl. It is the first NEUROLITH® in the capital of Bavaria, the largest German state.
In early May 2021, two more NEUROLITH® systems were installed in Germany. Both the renowned Klinikum Wahrendorff in Sehnde near Hanover and the private practice of Prof. Dr Musa Citak in Hamburg are expanding their range of therapies with Transcranial Pulse Stimulation (TPS).
Transcranial Pulse Stimulation (TPS) for the treatment of Alzheimer's patients is now also available for patients in Switzerland. In early February 2021, the first NEUROLITH® system was successfully installed in the Praxis Alexander Russ in Zurich.
A study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in January 2022 investigates the long-term effects of Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system on human brain and behaviour.1 The randomised, sham-controlled and double-blinded study provides sham-controlled evidence for such effects for the first time.
Another study by Matt et al. (Medical University of Vienna, University Department of Neurology) published in February 2022 now presented a detailed sub-analysis of possible anti-depressive effects of Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system based on neuropsychological and functional...
In December 2019, the first study1 on Transcranial Pulse Stimulation (TPS) with STORZ MEDICAL’s NEUROLITH® system was published in the prestigious journal Advanced Science. In the study, Beisteiner et al. evaluate the TPS method and present treatment results. The presented data shows that it is possible to improve brain performance with TPS and that there is a long-term effect.
Throughout the world, more and more specialised medical centres are using Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system for the treatment of patients with Alzheimer’s disease. In June 2020, another NEUROLITH® system was installed successfully at the private hospital »Rudolfinerhaus Privatklinik« in Vienna, Austria, where it will be used under the medical direction of Dr Matthias Geisler. On-site training of the hospital’s treatment team was carried out by Dr Henning Lohse-Busch (Rheintalklinik, Bad Krozingen, Germany) who also played a decisive role in the development of TPS.